文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌术后放疗后严重淋巴细胞减少的预后:长期随访研究结果

Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-03-12

该研究回顾性分析了1998至2017年间170例接受术后放疗的可切除非小细胞肺癌患者,严重放射性淋巴细胞减少(sRIL)发生率为32.3%。sRIL与计划靶区照射分次数及全肺平均剂量相关,且在多变量分析中显著降低总生存(HR 1.95,p<0.01),在III期患者中亦显著降低总生存(HR 1.88,p=0.004)。

要点

  • sRIL发生率为32.3%,与计划靶区照射分次数和全肺平均剂量独立相关。
  • sRIL患者中位无进展生存14.8个月、总生存28.4个月,均显著劣于无sRIL者。
  • III期患者中sRIL仍显著降低总生存(HR 1.88,p=0.004)。

核心结论

  • 严重放射性淋巴细胞减少与全肺平均剂量及照射分次数相关,是术后放疗患者生存不良的强预后因素,尤其在III期非小细胞肺癌中。

研究设计与样本

  • 回顾性队列研究,纳入1998至2017年间170例接受术后放疗的非小细胞肺癌患者,中位随访12.2年。

主要发现

  • sRIL发生率为32.3%。
  • 多变量逻辑回归显示sRIL与计划靶区照射分次数(OR 1.09,p=0.005)和全肺平均剂量(OR 1.12,p=0.006)相关。
  • sRIL患者中位无进展生存14.8个月 vs 无sRIL者21.7个月(p=0.008)。
  • sRIL患者中位总生存28.4个月 vs 无sRIL者48.3个月(p=0.01)。
  • 多变量分析显示sRIL显著降低总生存(HR 1.95,p<0.01);III期亚组中亦显著降低总生存(HR 1.88,p=0.004)。

关键数值与推荐

  • 严重淋巴细胞减少定义为绝对淋巴细胞计数<0.37×10^3/ul。

临床怎么用

  • 术后放疗计划设计时应关注全肺平均剂量和照射分次数,以降低严重淋巴细胞减少风险。
  • 对发生严重淋巴细胞减少的患者,尤其III期患者,应加强预后评估和随访。

局限性

  • 回顾性研究设计。
  • I-II期术后放疗多因切缘阳性,可能混杂严重淋巴细胞减少的贡献,故单独分析III期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the incidence and prognosis of severe radiation-induced lymphopenia (sRIL) after postoperative radiotherapy (PORT) for resected NSCLC. PATIENTS AND METHODS: Between 1998 and 2017, 170 patients treated with PORT for NSCLC were retrospectively reviewed. Lymphopenia was divided into tertiles with severe lymphopenia defined as absolute lymphocyte counts (ALC) < 0.37 × 103/ul. RESULTS: sRIL was observed in 32.3% of patients. Multivariable logistic regression analysis indicated sRIL was associated with planning target volume radiation fraction numbers (OR 1.09, p = 0.005) and total lung mean dose (OR 1.12, p = 0.006). With a median follow-up time of 12.2 years, the median progression-free survival and overall survival were 14.8 months and 28.4 months respectively in patients with sRIL, vs. 21.7 months (p = 0.008) and 48.3 months (p = 0.01) respectively in patients without sRIL. Multivariable analyses indicated sRIL significantly decreased OS (HR 1.95, p < 0.01). Since PORT for stage I-II NSCLC was done largely for positive margins, which may confound the contribution of severe RIL, we analyzed stage III separately and found that sRIL also significantly decreased OS (HR 1.88, p = 0.004) in multivariable analysis. CONCLUSION: For this long-term outcome study, severe RIL correlated with total lung mean dose and radiation fractionation numbers, and was a strong prognostic factor for poor survival in PORT patients, particularly in patients with stage III NSCLC, highlighting the importance of an intact immune system for post-radiation immunologic disease surveillance.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jing W, Liu Y, Zhu H, et al. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol. 2021. PMID: 33778173. doi:10.1016/j.ctro.2021.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。